Brief: Compass Therapeutics Announces Clinical Collaboration With Merck To Evaluate Ctx-471 In Combination With Keytruda® (Pembrolizumab)
11/10/2022 13:18
Oct 11 (Reuters) - Compass Therapeutics Inc. CMPX.O :
* COMPASS THERAPEUTICS ANNOUNCES CLINICAL COLLABORATION WITH
MERCK
TO EVALUATE CTX-471 IN COMBINATION WITH KEYTRUDA®
(PEMBROLIZUMAB)
* COMPASS THERAPEUTICS INC. - UNDER AGREEMENT, COMPASS IS
STUDY
SPONSOR, AND MERCK WILL PROVIDE CLINICAL SUPPLY OF KEYTRUDA
* COMPASS THERAPEUTICS INC. - COMPANIES WILL FORM A JOINT
DEVELOPMENT COMMITTEE TO REVIEW CLINICAL TRIAL RESULTS
Source text for Eikon: ID:nGNX8CRgQJ
Further company coverage: CMPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback